Rogers A - Search Results

1

Different effects of raloxifene and estrogen on interleukin-1beta and interleukin-1 receptor antagonist production using in vitro and ex vivo studies.

Rogers A, Clowes JA, Pereda CA, Eastell R. Rogers A, et al. Bone. 2007 Jan;40(1):105-10. doi: 10.1016/j.bone.2006.07.011. Epub 2006 Aug 24. Bone. 2007. PMID: 16934544

2

Effects of estrogen therapy of postmenopausal women on cytokines measured in peripheral blood.

Rogers A, Eastell R. Rogers A, et al. J Bone Miner Res. 1998 Oct;13(10):1577-86. doi: 10.1359/jbmr.1998.13.10.1577. J Bone Miner Res. 1998. PMID: 9783546 Free article.

3

The effect of 17beta-estradiol on production of cytokines in cultures of peripheral blood.

Rogers A, Eastell R. Rogers A, et al. Bone. 2001 Jul;29(1):30-4. doi: 10.1016/s8756-3282(01)00468-9. Bone. 2001. PMID: 11472888

4

Establishing a reference range for bone turnover markers in young, healthy women.

Glover SJ, Garnero P, Naylor K, Rogers A, Eastell R. Glover SJ, et al. Among authors: rogers a. Bone. 2008 Apr;42(4):623-30. doi: 10.1016/j.bone.2007.12.218. Epub 2008 Jan 5. Bone. 2008. PMID: 18289953

5

A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy.

Rogers A, Glover SJ, Eastell R. Rogers A, et al. Bone. 2009 Dec;45(6):1044-52. doi: 10.1016/j.bone.2009.07.089. Epub 2009 Aug 7. Bone. 2009. PMID: 19665601 Clinical Trial.

6

Rapid and robust response of biochemical markers of bone formation to teriparatide therapy.

Glover SJ, Eastell R, McCloskey EV, Rogers A, Garnero P, Lowery J, Belleli R, Wright TM, John MR. Glover SJ, et al. Among authors: rogers a. Bone. 2009 Dec;45(6):1053-8. doi: 10.1016/j.bone.2009.07.091. Epub 2009 Aug 11. Bone. 2009. PMID: 19679211 Clinical Trial.

7

Biochemical markers as predictors of rates of bone loss after menopause.

Rogers A, Hannon RA, Eastell R. Rogers A, et al. J Bone Miner Res. 2000 Jul;15(7):1398-404. doi: 10.1359/jbmr.2000.15.7.1398. J Bone Miner Res. 2000. PMID: 10893690 Free article.

8

Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women.

Rogers A, Saleh G, Hannon RA, Greenfield D, Eastell R. Rogers A, et al. J Clin Endocrinol Metab. 2002 Oct;87(10):4470-5. doi: 10.1210/jc.2002-020396. J Clin Endocrinol Metab. 2002. PMID: 12364420

9

Effects of raloxifene and alendronate on bone turnover as assessed by procollagen type I N-terminal propeptide.

Eastell R, Rogers A, Ni X, Krege JH. Eastell R, et al. Among authors: rogers a. Osteoporos Int. 2011 Jun;22(6):1927-34. doi: 10.1007/s00198-010-1380-5. Epub 2010 Sep 14. Osteoporos Int. 2011. PMID: 20838771 Clinical Trial.

10

Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment.

Rogers A, Eastell R. Rogers A, et al. J Clin Endocrinol Metab. 2005 Nov;90(11):6323-31. doi: 10.1210/jc.2005-0794. Epub 2005 Aug 16. J Clin Endocrinol Metab. 2005. PMID: 16105967 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,491 results

Search Page

Filters